Trade

with

CEL-SCI Corp
(Amex: CVM)
AdChoices
0.6900
+0.0200
+2.99%
After Hours :
-
-
-

Open

0.6800

Previous Close

0.6700

Volume (Avg)

623.67k (325.63k)

Day's Range

0.6675-0.7199

52Wk Range

0.5301-1.90

Market Cap.

54.98M

Dividend Rate ( Yield )

-

Beta

1.08

Shares Outstanding

79.68M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 159.58k

    • Net Income

    • -9.17M

    • Market Cap.

    • 54.98M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -10,848.17

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.08

    • Forward P/E

    • -1.97

    • Price/Sales

    • 163.93

    • Price/Book Value

    • 3.66

    • Price/Cash flow

    • -1.67

      • EBITDA

      • -8.64M

      • Return on Capital %

      • -115.07

      • Return on Equity %

      • -201.10

      • Return on Assets %

      • -115.07

      • Book Value/Share

      • 0.19

      • Shares Outstanding

      • 79.68M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 7.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.35

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -86.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 99.38

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -10,320.24

            • 39.38

            • Net Profit Margin

            • -10,848.17

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -12,273.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.00

              • 0.76

              • Current Ratio

              • 5.22

              • 2.92

              • Quick Ratio

              • 4.36

              • 2.35

              • Interest Coverage

              • -131.63

              • 38.02

              • Leverage Ratio

              • 1.67

              • 2.21

              • Book Value/Share

              • 0.19

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.50

                • 243.90

                • P/E Ratio 5-Year High

                • -32.67

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.15

                • 124.82

                • Price/Sales Ratio

                • 163.93

                • 9.29

                • Price/Book Value

                • 3.66

                • 8.39

                • Price/Cash Flow Ratio

                • -1.67

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -201.10

                    (-174.10)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -115.07

                    (-76.10)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -190.05

                    (-157.10)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.01

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -19.87M
                  Operating Margin
                  -12,450.12
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.67
                  Ownership

                  Institutional Ownership

                  5.48%

                  Top 10 Institutions

                  6.36%

                  Mutual Fund Ownership

                  2.41%

                  Float

                  98.39%

                  5% / Insider Ownership

                  19.79%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,023,611

                  • 0.00

                  • 1.28

                  • Vanguard Extended Market Index Fund

                  •  

                    408,553

                  • 0.67

                  • 0.51

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    239,050

                  • 0.00

                  • 0.30

                  • iShares Micro-Cap

                  •  

                    164,936

                  • 0.00

                  • 0.15

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    28,340

                  • 0.00

                  • 0.04

                  • Vanguard Balanced Index Fund

                  •  

                    21,336

                  • -53.04

                  • 0.03

                  • Vanguard Instl Total Stock Market Index

                  •  

                    15,977

                  • 0.00

                  • 0.02

                  • Master Extended Market Index Series

                  •  

                    14,672

                  • 0.00

                  • 0.02

                  • The Vanguard - Total Stk Mkt Idx Trust. CF

                  •  

                    13,012

                  • 0.00

                  • 0.02

                  • FlexShares Mstar US Mkt Factors Tilt ETF

                  •  

                    11,696

                  • 0.00

                  • 0.01

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • BlackRock Fund Advisors

                  •  

                    1,871,662

                  • +4.06%

                  • 2.83

                  • Vanguard Group, Inc.

                  •  

                    1,470,773

                  • +24.26%

                  • 2.23

                  • Geode Capital Management, LLC

                  •  

                    223,630

                  • 0.00%

                  • 0.34

                  • Northern Trust Investments, N.A.

                  •  

                    99,726

                  • +38.77%

                  • 0.15

                  • Rotella Capital Management Inc

                  •  

                    68,600

                  • +12.83%

                  • 0.11

                  • Brown Advisory Securities, LLC

                  •  

                    60,000

                  • 0.00%

                  • 0.09

                  • FineMark National Bank & Trust

                  •  

                    34,500

                  • 0.00%

                  • 0.05

                  • BNY Mellon Asset Management Ltd.

                  •  

                    31,223

                  • +0.39%

                  • 0.05

                  • Guggenheim Capital LLC

                  •  

                    25,647

                  • +6.52%

                  • 0.04

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  CEL-SCI Corp was incorporated on March 22, 1983, in the state of Colorado. The Company is engaged in the research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the bo...moredy's natural defense system. Its investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. The Company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. The ...moreCompany has operations in Vienna, Virginia, and in/near Baltimore, Maryland.lessless

                  Key People

                  Geert R. Kersten

                  CEO/CFO/Chief Accounting Officer/Director/Treasurer

                  Maximilian De Clara

                  Chairman of the Board/Director/President

                  Dr. Peter R. Young,PhD

                  Director

                  Alexander G. Esterhazy

                  Director

                  Dr. C. Richard Kinsolving,PhD

                  Director

                  • CEL-SCI Corp

                  • 8229 Boone Boulevard

                  • Vienna, VA 22182

                  • USA.Map

                  • Phone: +1 703 506-9460

                  • Fax: +1 703 506-9471

                  • cel-sci.com

                  Incorporated

                  1983

                  Employees

                  44

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: